VJHemOnc Podcast

CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes

Feb 27, 2025

Discover groundbreaking updates on CAR T-cell therapy for acute lymphoblastic leukemia. Experts discuss the pivotal CART19-BE-02 trial results and the FDA approval of obecabtagene autoleucel for relapsed B-ALL. Insights into the safety and efficacy of brexucabtagene autoleucel for older patients highlight promising outcomes. Innovative trials, including a phase two study of WU-CAR and tri-specific CAR T-cells, showcase strong safety profiles and exciting potential for future treatments in hematological malignancies.

18:39

Creator website

AI Summary

AI Chapters

Episode notes

Podcast summary created with Snipd AI

Quick takeaways

The pivotal CART19-BE-02 trial demonstrated an 84% complete response rate in adult patients with R/R B-ALL, establishing CAR T-cell efficacy.

Bridging therapy with inotuzumab improved CAR T-cell expansion and post-treatment survival, highlighting the importance of managing disease burden beforehand.

Deep dives

Advancements in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia

Current research highlights significant advancements in CAR T-cell therapy, particularly focusing on the treatment of adult patients with relapsed refractory B-cell acute lymphoblastic leukemia (ALL). A pivotal multicenter trial tested the CAR T product VARCELL, increasing the dose to three million CAR T-cells per kilogram and observing a notable complete response rate, reaching 84% in patients who received at least one treatment. The trial met its primary endpoint, demonstrating efficacy with undetectable minimal residual disease and leading to possible marketing authorization in Europe. This represents a significant step for academic-led CAR T-cell products, as achieving such results may pave the way for widespread clinical application.

Intro

6min

Advancements in CAR T-cell Therapy for Acute Lymphoblastic Leukemia

3min

Evaluating CAR T-cell Therapy in Older Adults with B-cell ALL

4min

Advancements in CAR-T Therapy: Phase Two Trial Results of WU-CAR

3min

Initial Results of Tri-Specific CAR T-Cell Therapy in Relapsed B-Cell Malignancies

3min

CAR T-cell therapy has become an established treatment for several hematological malignancies, including acute lymphoblastic leukemia (ALL), and has significantly changed the therapeutic landscape for patients. In this podcast episode, renowned experts will share insight into the use of CAR-T in ALL, including updates of pivotal trials, novel approaches being explored, and real-world outcomes.

First, you will hear from Valentín Ortiz-Maldonado, MD, Hospital Clinic Barcelona, Barcelona, Spain, who shares the results of the pivotal CART19-BE-02 trial (NCT04778579), a multicenter study investigating varnimcabtagene autoleucel (var-cel) in adult patients with relapsed/refractory (R/R) B-cell ALL (B-ALL). Following this, Pere Barba, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain, and Jae Park, MD, Memorial Sloan Kettering Cancer Center, New York, NY, provide valuable insight into findings from the FELIX trial (NCT04404660), the results of which led to the FDA approval of obecabtagene autoleucel (obe-cel) for adult patients with R/R B-ALL in November 2024. Next, Ibrahim Muhsen, MD, Baylor University Medical Center, Dallas, TX, shares the findings of a retrospective analysis evaluating the efficacy and safety of brexucabtagene autoleucel (brexu-cel) in older patients with R/R B-ALL. Finally, you will hear some updates of trials assessing novel CAR-T approaches in ALL from Armin Ghobadi, MD, Washington University School of Medicine, St. Louis, MO, and Evandro Bezerra, MD, The Ohio State University Comprehensive Cancer Center, Columbus, OH.

The post CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes appeared first on VJHemOnc.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

VJHemOnc Podcast

CAR T-cell therapy in ALL: trial updates, novel approaches, & real-world outcomes

Podcast summary created with Snipd AI

Quick takeaways

Deep dives

Advancements in CAR T-Cell Therapy for Acute Lymphoblastic Leukemia

Impact of Bridging Therapy on CAR T-Cell Expansion

Real-World Outcomes of CAR T-Cell Therapy in Older Patients

Remember Everything You Learn from Podcasts